Format

Send to

Choose Destination
Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302.009.

LBA-010Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

Author information

1
Mayo Clinic, Rochester, MN.
2
Alliance Statistics and Data Center, Rochester, MN.
3
HalioDx, Marseille, France.
4
Northwestern University, Chicago, IL.
5
British Columbia Cancer Agency, Vancouver, BC, CAN.
6
Ohio State University Cancer Center, Columbus, OH.
7
Surgical Oncology Associates of South Texas, San Antonio, TX.
8
Lehigh Valley Hospital, Allentown, PA.
9
Karmanos Cancer Institute, Detroit, MI.
10
Laboratory of Integrative Cancer Immunology, INSERM, Paris, FR.
PMID:
30052792
DOI:
10.1093/annonc/mdx302.009

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center